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Introduction
Gastrointestinal involvement in Behçet’s syndrome (BS)
can be a severe complication resulting in perforation and
massive bleeding. Controlled data regarding treatment is
lacking and long term prognosis is not well known.
Objectives
To report the demographic and disease characteristics,
type of involvement, treatment modalities and outcome
of BS patients with gastrointestinal involvement (GIBS).
Methods
We retrospectively reviewed the charts of all BS patients
evaluated with a suspicion of gastrointestinal involvement.
We identified those with GIBS and surveyed their demo-
graphic features, other BS manifestations, clinical, endo-
scopic and histologic gastrointestinal findings, and
treatment modalities. Patients were evaluated either in the
outpatient clinic or if not possible by phone calls to assess
their outcome.
Results
Among the 8058 recorded BS patients in our multidisci-
plinary outpatient clinic, 69 had symptoms suggesting gas-
trointestinal involvement and lesions on endoscopy.
Among these, 18 patients had other reasons for their gas-
trointestinal symptoms and endoscopic lesions. The
remaining 51 patients had GIBS (Table). The presenting
symptoms were acute abdomen caused by perforations in
4/51 patients, massive bleeding in 8/51 patients and
abdominal pain and/or diarrhea in 39/51 patients. Surgery
had to be performed in 20/51 patients, and 4 of them had
to be re-operated for development of stricture, progressive
disease, relapse, and corrective surgery, 1 patient each.
The most commonly used drugs for initial management
were azathioprine 2-2.5 mg/kg/day (n=33) and 5 ASA
compounds 3-4 g/day (n=13). Remission was observed
and there were no relapses during a mean follow-up of
44.3±46.9 months in 22/33 (67%) patients who had initi-
ally been prescribed azathioprine (2.5 mg/kg) and during
45.0±50.1 months in 9/13 (68%) patients who had been
prescribed 5 ASA compounds. Other than the 33 patients
who used azathioprine as their initial treatment, remission
was also obtained with azathioprine in 3/4 patients who
were resistant to 5 ASA compounds. Among the 10
patients who had relatively severe symptoms and persis-
tent large ulcers despite at least 6 months of azathioprine
treatment, endoscopic and symptomatic remission could
be obtained with thalidomide in 4 patients, infliximab in
4 patients and adalimumab in 2 patients. After a mean fol-
low-up of 7.1± 4.8 years (range 0.25 – 17 years), 42 (84%)
patients were in remission and 14 (28%) of these were off
treatment. Four (8%) patients were still active, 3 (6%)
patients had died due to non-GI releated reasons and
2 (4%) were lost to follow-up. The reasons for death were
pulmonary artery thrombosis, infection and acute renal
failure due to amyloidosis in 1 patient each.
Conclusion
84% of patients with GIBS were in remission after a mean
of 7 years of follow-up. Surgery was required in 40% of
patients with GIBS. 5 ASA compounds or azathioprine
provided remission and prevented relapses in two thirds of
the patients .The latter was also beneficial in some patients
resistant to 5 ASA compounds. Resistant and relapsing
cases could be managed with thalidomide or TNF-alpha
antagonists.
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